Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmathen

Full company profile

uuid00098a9

Namestring
Pharmathen
Websiteurl
pharmathen.com
Company typeenum
Private
Founded yearint
1969
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAmstelveen, Netherlands
HQ citystring
Amstelveen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, generic injectable drugs, advanced drug delivery, CDMO services, active pharmaceutical ingredients
Industry2 codes
1Contract Development & Manufacturing for Generics (CDMO/CMO)
CodeHLAIABAIPrimaryYes
2Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
CodeHLAGABABPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
Revenue model1 record
1Contract Manufacturing Services
TypeOthers
Description

Provides contract development and manufacturing services for pharmaceutical products, including injectable drugs, serving as an exclusive manufacturer for products like Lanreotide for Cipla

pharmiweb.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pharmathen is a Greek-headquartered pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). It specializes in advanced drug delivery, particularly the development and manufacturing of complex injectable pharmaceutical products and active pharmaceutical ingredients for global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pharmathen is a Greek pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO) specializing in advanced drug delivery solutions. Based on the available sources, Pharmathen manufactures injectable pharmaceutical products, including Lanreotide (a somatostatin analog used for treating acromegaly and neuroendocrine tumors), at their Rodopi facility in Greece. The company is positioned within the global advanced drug delivery CDMO market alongside competitors such as Evonik Health Care, SHL Medical, and Lubrizol Life Science. Pharmathen serves as a manufacturing partner for pharmaceutical companies including Cipla, supplying products exclusively for the US market. The company's capabilities include manufacturing of sterile injectable drug products with regulatory compliance for global markets including US FDA requirements.

Product and service4 records
1Lanreotide Injection
CategoryInjectable Generic Pharmaceuticals
2Advanced Drug Delivery Systems
CategoryCDMO Services
3Injectable Pharmaceutical Manufacturing Services
CategoryContract Manufacturing
4Active Pharmaceutical Ingredient (API) Manufacturing
CategoryAPI Manufacturing
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Cipla
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Pharmathen is the exclusive manufacturer of Lanreotide Injection for Cipla USA Inc. The Rodopi facility in Greece is the sole supplier of this key product, which is among Cipla's top three US products. The partnership has been disrupted due to FDA compliance issues at the facility.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Catalent
TypeBroad incumbent
Description

Large global CDMO with significant sterile injectable and biologics fill-finish operations. A broad incumbent that competes with Pharmathen for injectable pharmaceutical contracts but operates at significantly greater scale across multiple dosage forms and modalities.

2Fareva
TypeDirect peer
Description

French-headquartered CDMO operating sterile injectable manufacturing facilities in Europe, including for advanced drug delivery formats. Directly comparable contract manufacturing services to Pharmathen's injectable CDMO offerings.

3Corden Pharma
TypeDirect peer
Description

Peptide and injectable CDMO with integrated API-to-drug-product capabilities. Comparable to Pharmathen given peptide injectable manufacturing (Lanreotide) and integrated development services for complex parenteral products.

4Aenova Group
TypeDirect peer
Description

European CDMO with strong sterile injectable and aseptic fill-finish capabilities serving pharmaceutical companies globally. Comparable to Pharmathen's injectable manufacturing and advanced drug delivery focus.

5Recipharm
TypeDirect peer
Description

Swedish-headquartered CDMO with significant sterile injectable manufacturing capabilities and a generic-pharma customer base. Directly comparable business model to Pharmathen as a parenteral-focused CDMO serving branded and generic pharma.

6Patheon (Thermo Fisher Scientific)
TypeBroad incumbent
Description

Part of Thermo Fisher's pharma services segment, offering contract development and manufacturing including sterile injectables. A broad incumbent with substantially larger scale that competes with Pharmathen in injectable CDMO services.

7SHL Medical
TypeDirect peer
Description

Named alongside Pharmathen in the advanced drug delivery CDMO market. SHL Medical specializes in injectable drug delivery systems and auto-injector device manufacturing, directly overlapping with Pharmathen's injectable CDMO positioning.

8Evonik Health Care
TypeDirect peer
Description

Explicitly listed alongside Pharmathen as a major player in the global advanced drug delivery CDMO market. Evonik Health Care offers comparable parenteral drug delivery and CDMO services, directly competing for injectable pharmaceutical contracts.

9Lubrizol Life Science
TypeDirect peer
Description

Listed as a peer in the advanced drug delivery CDMO space. Lubrizol Life Science provides contract development and manufacturing for complex drug delivery formats including parenterals, making it a directly comparable CDMO peer.

10Acino International AG
TypeDirect peer
Description

Co-listed with Pharmathen among global advanced drug delivery CDMOs. Acino offers contract manufacturing for modified-release and specialty pharmaceutical products, including injectables, directly comparable to Pharmathen's service offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmathen

Pharmaceutical Contract Manufacturingpharmathen.com

Pharmathen firmographics

Firmographics
Name
Pharmathen
Website
https://pharmathen.com
Company type
Private
Founded year
1969
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Pharmathen industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
akta.pro secondary industry
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

  • Contract pharmaceutical manufacturing
  • Generic injectable drugs
  • Advanced drug delivery
  • CDMO services
  • Active pharmaceutical ingredients

Where Pharmathen is headquartered

Location

Headquarters

HQ city
Amstelveen
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Pharmathen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Contract Manufacturing Services: Provides contract development and manufacturing services for pharmaceutical products, including injectable drugs, serving as an exclusive manufacturer for products like Lanreotide for Cipla

Distribution channels1 record

Pharmathen product offering

Product offering

Core offering

Pharmathen is a Greek-headquartered pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). It specializes in advanced drug delivery, particularly the development and manufacturing of complex injectable pharmaceutical products and active pharmaceutical ingredients for global pharmaceutical partners.

Product overview

Pharmathen is a Greek pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO) specializing in advanced drug delivery solutions. Based on the available sources, Pharmathen manufactures injectable pharmaceutical products, including Lanreotide (a somatostatin analog used for treating acromegaly and neuroendocrine tumors), at their Rodopi facility in Greece. The company is positioned within the global advanced drug delivery CDMO market alongside competitors such as Evonik Health Care, SHL Medical, and Lubrizol Life Science. Pharmathen serves as a manufacturing partner for pharmaceutical companies including Cipla, supplying products exclusively for the US market. The company's capabilities include manufacturing of sterile injectable drug products with regulatory compliance for global markets including US FDA requirements.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lanreotide Injection
  • Advanced Drug Delivery Systems
  • Injectable Pharmaceutical Manufacturing Services
  • Active Pharmaceutical Ingredient (API) Manufacturing

Companies that use Pharmathen

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Pharmathen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pharmathen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CiplacoreOEM/ Whitelabel/ Licensing PartnerPharmathen is the exclusive manufacturer of Lanreotide Injection for Cipla USA Inc. The Rodopi facility in Greece is the sole supplier of this key product, which is among Cipla's top three US products. The partnership has been disrupted due to FDA compliance issues at the facility.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Pharmathen competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Large global CDMO with significant sterile injectable and biologics fill-finish operations. A broad incumbent that competes with Pharmathen for injectable pharmaceutical contracts but operates at significantly greater scale across multiple dosage forms and modalities.
  • Patheon (Thermo Fisher Scientific): Part of Thermo Fisher's pharma services segment, offering contract development and manufacturing including sterile injectables. A broad incumbent with substantially larger scale that competes with Pharmathen in injectable CDMO services.

Direct peers

  • Fareva: French-headquartered CDMO operating sterile injectable manufacturing facilities in Europe, including for advanced drug delivery formats. Directly comparable contract manufacturing services to Pharmathen's injectable CDMO offerings.
  • Corden Pharma: Peptide and injectable CDMO with integrated API-to-drug-product capabilities. Comparable to Pharmathen given peptide injectable manufacturing (Lanreotide) and integrated development services for complex parenteral products.
  • Aenova Group: European CDMO with strong sterile injectable and aseptic fill-finish capabilities serving pharmaceutical companies globally. Comparable to Pharmathen's injectable manufacturing and advanced drug delivery focus.
  • Recipharm: Swedish-headquartered CDMO with significant sterile injectable manufacturing capabilities and a generic-pharma customer base. Directly comparable business model to Pharmathen as a parenteral-focused CDMO serving branded and generic pharma.
  • SHL Medical: Named alongside Pharmathen in the advanced drug delivery CDMO market. SHL Medical specializes in injectable drug delivery systems and auto-injector device manufacturing, directly overlapping with Pharmathen's injectable CDMO positioning.
  • Evonik Health Care: Explicitly listed alongside Pharmathen as a major player in the global advanced drug delivery CDMO market. Evonik Health Care offers comparable parenteral drug delivery and CDMO services, directly competing for injectable pharmaceutical contracts.
  • Lubrizol Life Science: Listed as a peer in the advanced drug delivery CDMO space. Lubrizol Life Science provides contract development and manufacturing for complex drug delivery formats including parenterals, making it a directly comparable CDMO peer.
  • Acino International AG: Co-listed with Pharmathen among global advanced drug delivery CDMOs. Acino offers contract manufacturing for modified-release and specialty pharmaceutical products, including injectables, directly comparable to Pharmathen's service offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Pharmathen social profiles

Digital presence

Pharmathen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmathen leadership team

Management profile

Number of profiles

Profiles2 records

Pharmathen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmathen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmathen

What does Pharmathen do?

Pharmathen is a Greek-headquartered pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). It specializes in advanced drug delivery, particularly the development and manufacturing of complex injectable pharmaceutical products and active pharmaceutical ingredients for global pharmaceutical partners.

Is Pharmathen a public or private company?

Pharmathen is a private company. It is classified as unknown and is currently operating.

When was Pharmathen founded?

Pharmathen was founded in 1969. It employs 501 to 1,000 people.

Where is Pharmathen based?

Pharmathen is headquartered in Amstelveen, Netherlands, in the Europe region.

How does Pharmathen make money?

One revenue line is on record: contract Manufacturing Services.

Who are Pharmathen's main competitors?

Broad incumbents on record are Catalent and Patheon (Thermo Fisher Scientific). Direct peers are Fareva, Corden Pharma, Aenova Group, Recipharm, SHL Medical, Evonik Health Care, Lubrizol Life Science and Acino International AG.

Does Pharmathen have an API?

No public API is recorded for Pharmathen.

What industry is Pharmathen in?

Pharmathen's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
QuotedDataPartners Group Private Equity writes off £17m Pharmathen investment after Greek company hit by FDA import alertPartners Group Private Equity has written off a £17m investment in Pharmathen following an FDA import alert that affected the Greek company. The article also discusses various market movements and investments involving companies like Scottish Mortgage, Baillie Gifford, Saba Capital, and ICEYE.GreekcitytimesGreece-India ties are deepening Greek City TimesGreece and India are deepening economic ties ahead of Greek Prime Minister Kyriakos Mitsotakis' visit to India on February 18, driven by the concluded EU-India Free Trade Agreement negotiations that will substantially reduce tariffs on European agricultural exports to India, including olive oil (currently 45% tariff), kiwifruit, wine, and processed foods. The India-Middle East-Europe Economic Corridor (IMEC) positions Greece as a strategic gateway between India and European markets, with Greek ports serving as key hubs and Indian companies like GMR Infrastructure investing in Greek infrastructure such as the Kastelli airport in Crete. Direct air connectivity has launched with IndiGo's first flight to Greece and Aegean scheduled to begin Athens-New Delhi and Mumbai routes in March, while bilateral investment flows include Indian pharmaceutical company Intas/Accord and Greek firms Pharmathen, Alumil, and Frigoglass operating in each other's markets.Business TodayCipla Fell Nearly 5% After US FDA Flags Lapses At Greece-Based Pharmathen | Cipla NewsCipla's stock fell nearly 5% after the US FDA flagged serious compliance issues at its manufacturing partner Pharmathen's facility in Greece, specifically lapses in contamination control systems for the injectable drug Lanreotide. Lanreotide is a key product for Cipla in the US market, and the FDA findings could impact production timelines, regulatory approvals, and supply continuity until corrective actions are implemented. Both Cipla's response and Pharmathen's remediation measures will be closely monitored, as prolonged regulatory action could weigh on Cipla's US formulations business and investor sentiment.NDTV ProfitCipla Shares Fall 4% After USFDA Flags Compliance Issues At Pharmathen's Rodopi FacilityCipla's shares fell 4% to Rs 1,471.50 on Wednesday after the USFDA issued a Form 483 to its contract manufacturing partner Pharmathen, citing nine observations of cGMP violations at the Rodopi facility. The FDA flagged critical issues including microbiological contamination risks involving gram-negative bacteria, poor aseptic practices, inadequate investigations into out-of-specification results, and potential data integrity challenges. Since Lanreotide, Cipla's largest product in the U.S. market, is manufactured at Pharmathen's Rodopi unit, the compliance issues pose a potential risk to Cipla's revenue from the drug.NtcpharmaNTC acquires Pharmathen’s ophthalmology business, boosting its glaucoma portfolio and European market positionNTC S.r.l., an Italian pharmaceutical company focused on ophthalmology, has completed the acquisition of Pharmathen's ophthalmology business, which includes a consolidated global portfolio of glaucoma treatments manufactured in European and U.S. facilities. The transaction will enable NTC to reach approximately €100 million in revenues, with over 80% generated in ophthalmology, and to expand into the U.S. market through its established B2B commercial network. The acquisition reinforces NTC's position as a leading European ophthalmology player, extending its commercial reach to over 100 countries and 250 distribution partners.PR NewswireNTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESSNTC, supported by Wise Equity, completed the acquisition of Pharmathen's ophthalmology business, focusing on glaucoma treatments, expanding its revenue to around €100 million and extending its market presence to the U.S. and over 100 countries. The deal enhances NTC's ophthalmic portfolio and solidifies its position in the European eye care market.Pharmaceutical TechnologyPartners Group to acquire Pharmathen from BC Partners for $1.9bnPartners Group has agreed to acquire the European pharmaceutical company Pharmathen from BC Partners for an enterprise value of approximately $1.9 billion. The acquisition involves Pharmathen, a contract development and manufacturing organization specializing in drug delivery technologies for generic medicines with manufacturing sites in Greece. The deal is subject to regulatory approvals and is expected to conclude within the year.PR NewswireBC Partners Sells Pharmathen To Partners GroupBC Partners has sold a majority stake in Pharmathen, a leading European pharmaceutical company specializing in drug delivery technology, to Partners Group for approximately €1.6 billion. Founded in 1969 and acquired by BC Partners in 2015 for €475 million, Pharmathen has delivered strong growth under BC Partners' ownership, including 16% CAGR organic EBITDA growth over five years and over €250 million invested in R&D and FDA-approved production facilities. The transaction is subject to customary regulatory approvals and is expected to close in 2021.PR NewswireBC Partners Sells Pharmathen To Partners GroupBC Partners has announced the sale of a majority stake in pharmaceutical company Pharmathen to global private markets firm Partners Group for an enterprise value of approximately EUR 1.6 billion. Under BC Partners' ownership since 2015, Pharmathen expanded its portfolio to 85 products and invested over €250 million in R&D and FDA-approved facilities. The transaction is expected to close in 2021 subject to regulatory approvals.PR NewswireUpsher-Smith Enters into Exclusive development and Distribution Agreement with Pharmathen S.A.Upsher-Smith Laboratories announced an exclusive agreement with Pharmathen S.A. to develop and distribute a generic product in the United States, with Pharmathen handling development and manufacturing while Upsher-Smith submits the ANDA and handles marketing and distribution. The target market category represents more than $500 million in U.S. sales, according to IMS Health data for the 12 months ending July 2016. Financial terms of the agreement were not disclosed.